Table 1.
Basic characteristics of the included trials
| First author | Clinical trial registration number | Year | Phase | Sample size | Gender | Age | Treatment | Disease | Assessment (Response) | Assessment (AE) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | ||||||||||
| Yamamoto, K. | NCT00355472 | 2010 | I | 16 | 8 | 8 | 62 (46–69) | mogamulizumab | relapsed CCR4+ ATL or PTCL | RECIL | CTCAE |
| Ishida, T. | NCT00920790 | 2012 | II | 27 | 12 | 15 | 64 (49–83) | mogamulizumab | relapsed CCR4+ ATL | RECIL | CTCAE |
| Ogura, M. | NCT01192984 | 2014 | II | 37 | 23 | 14 | 64 (33–80) | mogamulizumab | relapsed CCR4+ PTCL or CTCL | RECIL | CTCAE |
| Duvic, M. | NCT00888927 | 2015 | I-II | 41 | 24 | 17 | 66 (35–85) | mogamulizumab | CTCL or PTCL | RECIL | CTCAE |
| Ishida, T. | NCT01173887 | 2015 | II | 53 | 28 | 25 | – | mLSG15 + mogamulizumab or mLSG15 | aggressive ATL | RECIL | CTCAE |
| Kurose, K. | NCT01929486 | 2015 | I | 10 | – | – | – | mogamulizumab | LC or EC | RECIST | CTCAE |
| Zinzani, P. L. | NCT01611142 | 2016 | II | 38 | 23 | 15 | 58.5 (19–87) | mogamulizumab | PTCL | RECIL | CTCAE |
| Ishitsuka, K. | UMIN000025368 | 2017 | II | 484 | 258 | 226 | – | mogamulizumab or mogamulizumab with other drugs | ATL and others | RECIL | CTCAE |
| Kim, Y. H. | NCT01728805 | 2018 | III | 372 | 216 | 156 | 64.5 (54–73) | mogamulizumab or vorinostat | CTCL | RECIL | CTCAE |
| Nakashima, J. | – | 2018 | – | 45 | 27 | 18 | 69 (43–89) | mogamulizumab | relapsed or refractory ATL | RECIL | CTCAE |
| Phillips, A. A. | NCT01626664 | 2018 | II | 34 | 37 | 71 | 53 (22–82) | mogamulizumab, pralatrexate, gemcitabine plus oxaliplatin or DHAP | ATL | RECIL | CTCAE |
| – | NCT02358473 | 2018 | I | 13 | 5 | 8 | – | mogamulizumab +docetaxel | NSCLC | RECIST | CTCAE |
| Doi, T. | NCT02476123 | 2019 | I | 96 | 72 | 24 | 63 (56–68) | mogamulizumab +nivolumab | NSCLC, SCLC, GC, EC, HCC, PA | RECIST | CTCAE |
| Cohen, E. E. W. | NCT02444793 | 2019 | I | 24 | 19 | 5 | 63.9 (53–75) | mogamulizumab +utomilumab | CRC, NSCLC, OC, SCCHN | RECIST | CTCAE |
Abbreviations: ATL adult T-cell leukemia-lymphoma, PTCL peripheral T-cell lymphoma, CTCL cutaneous T-cell lymphoma, LC lung cancer, EC esophageal cancer, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, GC gastric cancer, HCC hepatocellular carcinoma, PA pancreatic adenocarcinoma, CRC colorectal cancer, OC ovarian cancer, SCCHN squamous cell cancer of head and neck, mLSG15 modified LSG15 regimen (VCAP-AMP-VECP: vincristine, cyclophosphamide, doxorubicin and prednisolone; doxorubicin, ranimustine and prednisolone; vindesine, etoposide, carboplatin and prednisolone), AE adverse events, RECIL Response Evaluation Criteria in Lymphoma, RECIST Response Evaluation Criteria in Solid Tumors, CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events